Agenus To Present Chemo-Sparing BOT+BAL Immunotherapy Data In 1L MSS Colorectal Cancer At AACR 2026

Agenus Inc. (NASDAQ: AGEN) announced that it will present preliminary results from a study evaluating the combination of botensilimab (BOT) and balstilimab (BAL) in first-line microsatellite stable colorectal cancer (MSS CRC) at the AACR Annual Meeting 2026. This study, known as BBoPCO, aims to reduce reliance on cytotoxic chemotherapy by introducing immunotherapy earlier in treatment. Colorectal cancer remains a significant health issue, particularly in younger populations, with MSS mCRC representing about 95% of metastatic cases and showing limited benefit from traditional immunotherapy.